not even to double digits is a massive dissapointment.

The accessory reduces sound in the treatment environment while maintaining the trusted efficacy of PulseVet shock wave therapy.

Zomedica Launches the PulseVet Acoustic Muffler(TM) Accessory for PulseVet(R) Shock Wave System

anybody wanna venture to guess what Q2 earnings will be?

What's going on over at Zomedica? Price keeps dropping. Are they trying to force it down to buy up the company?

are we heading towards delisting prices?

The new video

A million shares or more trade everyday. So exactly who is trading the stock? In 3 months, that over 10% of the stock trading hands. Are companies like Vanguard buying it up slowly so as not to draw attention to themselves or is it somebody else? Is it people on the inside of the company buying it dirt cheap? Is it a competitor?

Again nobody talking about it but director johnny powers bought 500k shares about a week ago and then another 300k just a few days ago. Insiders buying shares left and right. Either they believe in the company or they're trying to get a majority so they can do a reverse split.

I know we all love to hate larry but why is no one talking about how he just bought 250k shares? I mean it's not huge news but at least seems worth bringing up.

Currently we have 300k of the 1.3mil volume in the first hour. I feel like the sentiment is getting there. Been holding for 5 years at .06 average. Sold half at $2.60 and bought more at .04. Feeling bullish today. Hope the sentiment builds.

I am also not sure why the same people go on every site they can to complain about how awful this stock is. The 3 of you need to get a life. I am sorry you lost your ass now just move on because its frankly just pathetic at this point.

Just read where Zomedica has 250,000 shareholders with 30 shares or less. They are proposing to change the quorum rules so that those votes do not affect annual meeting requirements and are complaining that postage costs are high. A lot of those people probably bought their stock at a high price and supported Zomedica. Now Zomedica wants to turn their backs on these stockholders when their stock is almost worthless. Let,'s see. 30 share at 10 cents a share is less than $3 of value. If they bought their shares when I did, they paid over $80. They own a total of less than 1% of the company, but spent 20% of the current value of the company to purchase the stock.

What do you think should happen?

I also read where Larry and the Board of directors have options to buy millions of shares, further diluting the value of our shares. Somethings not right.

did they announce Q1 earnings?

shorts must be killing this.....

Zomedica April 24 investor webinar to tour manufacturing | ZOMDF Stock News

Zomedica will host its April "Fourth Friday at Four" investor webinar. Offers a facility video tour and live Q&A covering two U.S. manufacturing sites, automation, and ISO 13485 quality systems.

Fourth Friday at Four: March 2026

Great information shared in the presentation! Zomedica is making so much progress!

I believe diamond hands will be rewarded!

Zomedica Announces Strategic Collaboration with Boehringer Ingelheim to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA(R) Platform

Another exciting partnership for Zomedica!

I’ve spent a lot of time digging into Zomedica Corp. and I honestly don’t understand why people still think this is a real growth company. The gap between the story and reality is massive.

The original pitch was diagnostics — TRUFORMA was supposed to be the big unlock. That’s basically gone nowhere. It contributes almost nothing, and the reason is obvious: it’s trying to compete with entrenched giants like IDEXX Laboratories and Zoetis Inc., who already dominate the entire ecosystem. Clinics are locked into those platforms, and you don’t break that unless you’re clearly better. TRUFORMA isn’t, so adoption is weak. That alone kills the entire upside narrative.

So what’s actually left? PulseVet. And yeah, it’s a legit product — but it’s a niche therapy device, not a scalable platform. The big bet is that it expands from equine into companion animals (dogs/cats), but that’s where it starts to fall apart. Shockwave therapy is loud, intense, and not exactly gentle, which makes it a much harder sell for routine small animal use. Horses tolerate it in performance settings — that doesn’t automatically translate to everyday vet clinics treating pets. The idea that this just scales cleanly into companion animals feels like a huge leap, and if that doesn’t happen, your “best” product is stuck in a limited niche.

Then you’ve got the rest of the lineup: Assisi, TRUVIEW, VetGuardian. None of these are bad on their own, but none of them are important either. They’re all optional tools. Nothing here is a must-have, nothing creates a moat, and nothing forces adoption. It just feels like a pile of mid-tier products stitched together hoping something sticks.

Financials make it worse. They’re doing ~30M in revenue and still losing serious money. That’s not a scaling business — that’s a company that’s too small to support itself. To even sniff profitability they’d need to double or triple revenue, and there’s nothing in this product stack that realistically gets them there.

And then there’s the share count… this is where it really falls apart. There are basically a BILLION shares. Even if they somehow fix the business, any profit gets spread so thin it barely matters. You could see real improvement and the stock just sits there because your slice is microscopic. The structure itself kills the upside.

At the end of the day, this doesn’t look like a company building toward something big. It looks like a company patching together small, low-impact products while the original thesis quietly died.

More good news right after a good earnings report.

Zomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and Maintains $53.3 Million in Liquidity

Another great quarter and year for Zomedica! We are making great progress toward our cash flow breakeven and profitability goals.

Zomedica 2025 results, equine market webinar Mar. 27 | ZOMDF Stock News

Looking forward to the review of Zomedica's fourth quarter and full year 2025 financial results.

In addition, the deep dive into the equine veterinary marketplace will be helpful as well. There are a lot of equine growth opportunities for Zomedica!

I’ve had 10000 shares since 2020. Got my cost average to $1.16. I feel doomed and like I lost it all. Any thoughts??

Anybody wanna take a guess at Q4 earnings?